Pain Phenotype and Response to Corticosteroid Injection in Patients With Subacromial Pain Syndrome (SAPS)
Not yet recruitingNCT07792421
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this prospective cohort study is to investigate whether pain phenotype is associated with subsequent change in pain intensity after corticosteroid injection given as part of routine care in patients diagnosed with SAPS. The main question it aims to answer is: Does change in shoulder pain from baseline to 4 weeks after corticosteroid injection differ between patients classified as having a nociplastic pain phenotype and those classified as having a non-nociplastic pain phenotype?
Study details
- Official title
- Association Between Pain Phenotype and Change in Pain Following Routine Corticosteroid Injection in Patients With Subacromial Pain Syndrome - A Prospective Cohort Study.
- Conditions
- Subacromial Pain Syndrome
- Rotator Cuff Related Shoulder Pain
- Shoulder Pain
- Shoulder Impingement Syndrome
- Saps
- Interventions
- Procedure: Clinical evaluation
- Sponsor
- Vejle Hospital
- Start date
- 2026-10-19
- Primary completion
- 2028-09-30
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Diagnosed with SAPS (dm751, dm753, dm754, dm755 2. Shoulder pain ≥ 3 months 3. ≥ 3 out of 5 specific shoulder test 4. Age 18-70 years 5. Increased pain during active arm elevation 6. Pain during active elevation ≥ 3 (VAS) 7. Receving a corticosteroid injection based on routine clinical proctice Exclusion Criteria: 1. Severe visual impairment 2. Epilepsy 3. Severe cognitive or physical impairment 4. Language barrier (Danish) 5. Receving a corticosteroid injection at a site other than the subacromial bursa (e.g. acromioclavicular joint or intra-articular injection)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07792421